Spinal Muscular Atrophy research hub
15 indexed studies · 7 currently recruiting
- authorisedTherapeutic confirmatory (Phase III)
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam
This phase 3 study tests an investigational medicine called salanersen (BIIB115) for people aged 15 to 60 with spinal muscular atrophy (SMA). Researchers want to see if it helps improve physical movement, arm strength, and walking ability over time in people new to treatment or previously treated with risdiplam.
Finland · Spain · Italy - recruitingTherapeutic confirmatory (Phase III)
A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen - ONWARD
This study looks at higher doses of a medicine called nusinersen (Spinraza) for spinal muscular atrophy (SMA). It is for people who were already in an earlier nusinersen study. Researchers want to see if higher doses are safe and help muscle strength over several years.
Italy · Spain · Germany - authorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy
This study tests a medicine called salanersen for babies with spinal muscular atrophy (SMA) who have already received gene therapy. Doctors want to see if salanersen is safe and whether it can give extra support to help infants build muscle strength, sit, crawl, and walk.
Portugal · Italy · Belgium - not yet recruiting
Spinal Muscular Atrophy and School Transitions
This study looks at how children and young people with Spinal Muscular Atrophy (SMA) and their families experience moving between schools and being involved in school life. They want to find out what makes it harder or easier, and how different services work together (or don't).
United Kingdom - recruitingTherapeutic use (Phase IV)
A Phase 4 Study of Nusinersen (BIIB058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec - RESPOND
This study looks at how well the medicine Spinraza (nusinersen) works for people with Spinal Muscular Atrophy (SMA) who have previously received another treatment called Zolgensma (onasemnogene abeparvovec). Researchers want to see if Spinraza can help improve movement and reduce problems for these patients.
Spain · Germany · Italy - active not recruitingNA
Quantification of Motor Function in Infants With Spinal Muscular Atrophy Treated With Innovative Therapies
This study aims to find a better way to measure movement in babies with Spinal Muscular Atrophy (SMA) who are receiving new treatments. We'll be using small, wearable sensors to track their motor skills more accurately than current methods.
France - active not recruitingNA
Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).
This study looks at a new and improved rehabilitation program for children aged 1-10 with Spinal Muscular Atrophy (SMA) in the UK. It aims to see if more frequent, hands-on therapy and home equipment can help children and be a good option for families.
United Kingdom - recruiting
UK SMA Patient Registry
This registry is for people with Spinal Muscular Atrophy (SMA) in the UK and Ireland. It gathers information online to help doctors and researchers better understand SMA, which is a condition that affects how muscles work. You can share details about your health and daily life.
United Kingdom - active not recruitingPHASE3
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
This study looks at the long-term safety and effects of a medicine called apitegromab for people with Spinal Muscular Atrophy (SMA) types 2 and 3. It's for those who have already completed earlier studies with this drug.
United States · Belgium · France - recruitingNA
Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy
This study looks at children under 16 with Spinal Muscular Atrophy (SMA) who are receiving new treatments. We want to understand how these treatments are changing the disease and find the best ways to check on patients' health and progress.
France - active not recruitingNA
Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
This study looks at how a treatment called Spinraza affects movement in adults with a type of muscular atrophy (SMA Type II). Researchers want to see if Spinraza helps improve or maintain muscle function over time in these patients. It's for adults already using a wheelchair.
France - active not recruitingPHASE3
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
This study looks at a higher dose of nusinersen for teenagers and adults with Spinal Muscular Atrophy (SMA) who can't walk and have previously taken risdiplam. Researchers want to see if this higher dose helps improve muscle and movement abilities, especially in the arms and hands, and to check its safety.
United States · Germany · Hungary - recruitingPHASE2
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
This study is looking at a new medicine called apitegromab for babies and toddlers under 2 years old who have a condition called spinal muscular atrophy (SMA). It aims to see how safe and effective the medicine is, how the body uses it, and if it helps with movement.
United States · Belgium · France - recruitingNA
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
This study is testing a new device, the ThecaFlex DRx System, for people with Spinal Muscular Atrophy (SMA) to make it easier to give them their medicine. It involves having the device implanted and then being monitored for a year.
United States · Germany · Poland - active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
This study looks at a new medicine called taldefgrobep alfa for young people with Spinal Muscular Atrophy (SMA). It's for those already on other SMA treatments to see if adding this new medicine can further improve muscle strength and movement.
United States · Belgium · Czechia